Literature DB >> 16156424

Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education.

Geoff I Hackett1.   

Abstract

Understanding patient preferences can be important in ensuring full benefit is derived from treatment for erectile dysfunction (ED). They seem to be important in determining whether patients continue treatment in the medium and long term. In clinical practice, discontinuation rates beyond a year are relatively high. Factors such as spontaneity, "naturalness", and onset and duration of action may all influence preference. This article discusses a number of studies looking into patient preferences for a particular class of treatment method over another, and also for individual treatments within classes. In general, patients appear to prefer oral treatments to others such as penile implant surgery, vacuum-pump therapy, apomorphine, and intracavernosal injection. In some studies, men have also shown preferences for particular oral phosphodiesterase-5 (PDE5) inhibitors over others. Providing patients with full information on the pros and cons of treatment options can help ensure patients are treated with a therapy that fits more closely with their wishes, and ensure continuation of treatment for optimal efficacy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156424     DOI: 10.1016/s1098-3597(05)80049-3

Source DB:  PubMed          Journal:  Clin Cornerstone        ISSN: 1873-4480


  12 in total

1.  Vacuum erection devices to treat erectile dysfunction and early penile rehabilitation following radical prostatectomy.

Authors:  Craig D Zippe; Geetu Pahlajani
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

Review 2.  Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.

Authors:  Sharon A Huang; Janette D Lie
Journal:  P T       Date:  2013-07

3.  Anticipatory guidance preferences of Latina migrant farmworker mothers.

Authors:  Jill F Kilanowski
Journal:  J Pediatr Health Care       Date:  2011-09-29       Impact factor: 1.812

4.  Effects of chronic treatment with the eNOS stimulator Impaza on penis length and sexual behaviors in rats with a high baseline of sexual activity.

Authors:  X Chu; E S Zhavbert; J L Dugina; I A Kheyfets; S A Sergeeva; O I Epstein; A Agmo
Journal:  Int J Impot Res       Date:  2013-03-14       Impact factor: 2.896

5.  Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms.

Authors:  H Choi; J-H Kim; J-S Shim; J Y Park; S H Kang; D G Moon; J Cheon; J G Lee; J J Kim; J-H Bae
Journal:  Int J Impot Res       Date:  2014-07-03       Impact factor: 2.896

Review 6.  Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review.

Authors:  Paul Williams; Hayley McBain; Aliya Amirova; Stanton Newman; Kathleen Mulligan
Journal:  Int J Impot Res       Date:  2020-03-31       Impact factor: 2.896

7.  Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers.

Authors:  Milko Radicioni; Chiara Castiglioni; Andrea Giori; Irma Cupone; Valeria Frangione; Stefano Rovati
Journal:  Drug Des Devel Ther       Date:  2017-04-11       Impact factor: 4.162

Review 8.  Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil.

Authors:  Emmanuele A Jannini; Stéphane Droupy
Journal:  Sex Med       Date:  2018-12-03       Impact factor: 2.491

9.  Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.

Authors:  Hyun Hwan Sung; Sung Won Lee
Journal:  Korean J Urol       Date:  2012-06-19

10.  Association of psychological factors, patients' knowledge, and management among patients with erectile dysfunction.

Authors:  Hasniza Zaman Huri; Nurul Diyana Mat Sanusi; Azad Hassan Abdul Razack; Raymond Mark
Journal:  Patient Prefer Adherence       Date:  2016-05-13       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.